All In Biotech

Drug Trial Radar · NCT06016088

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

Apr 1, 2024

Primary completion

Apr 15, 2026

Study completion Jun 22, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

Conditions

  • Cystic Fibrosis Lung
  • Respiratory Infections, Recurrent, Chronic
  • Pseudomonas Aeruginosa

Interventions

  • RSP-1502Drug

    RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.

  • Tobramycin inhalation solutionDrug

    Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventsTime frame: Day 1 through Day 28
  2. Treatment-emergent serious adverse eventsTime frame: Day 1 through Day 28
  3. Changes in post-dose spirometryTime frame: Day 1, Day 2, and Day 14
  4. Pulmonary exacerbationsTime frame: Day 1 through Day 28
  5. Changes in post-dose electrocardiogram resultsTime frame: Day 1, Day 2, and Day 14

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Tucson Cystic Fibrosis Center

    Tucson, Arizona

  • Center for Cystic Fibrosis at Keck Medical Center of USC

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • Augusta University

    Augusta, Georgia

  • The Cystic Fibrosis Institute

    Northfield, Illinois

  • Tulane University

    New Orleans, Louisiana

  • The Minnesota Cystic Fibrosis Center

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Cystic Fibrosis Program

    New York, New York

  • Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Dell Children's Medical Center of Central Texas

    Austin, Texas

  • Royal Prince Albert Hospital

    Camperdown, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Queensland Children's Hospital

    Brisbane, Queensland, Australia

  • The Prince Charles Hospital

    Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • Lung Institute of Western Australia

    Nedlands, Western Australia, Australia

  • The Kids Research Institute Australia, Perth Children's Hospital

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.